August 8, 2018 10:13 AM EDTUpdated 10:40 AM
People

In­sid­er trad­ing in Wash­ing­ton: NY Con­gress­man in­dict­ed for shar­ing in­side biotech tips ahead of mas­sive tri­al fail­ure

Brittany Meiling

A tiny Aus­tralian biotech that ex­pe­ri­enced a very pub­lic and ex­plo­sive clin­i­cal tri­al fail­ure is once again in the spot­light — this time, for its ties …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

A service from the Financial Times